REG - Spectral MD Holdings - Exercise of Options

Spectral MD HoldingsAnnouncement

25/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230825:nRSY4539Ka&default-theme=true

RNS Number : 4539K  Spectral MD Holdings, Ltd.  25 August 2023

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company")

 

Exercise of Options

 

LONDON, U.K. AND DALLAS, TX, U.S. -Spectral MD Holdings, Ltd. (AIM: SMD), an
artificial intelligence (AI) company focused on medical diagnostics for faster
and more accurate treatment decisions in wound care, announces the exercise
of options (the "Exercise") by certain employees of the Company including the
Company's CEO, Wensheng Fan (together the "Employees") as detailed below.

 

The Employees have exercised options over an aggregate of 1,155,159 shares of
common stock of US$0.001 each in the Company ("Common Stock").

 

796,587 shares of Common Stock have been issued and allotted pursuant to the
Company's 2018 Long-Term Incentive Plan. As previously announced on 7 November
2022, up to 2 million shares of Common Stock under the 2018 Long-Term
Incentive Plan were previously admitted to trading on AIM pursuant to a block
listing application. A further 358,572 shares of Common Stock have been issued
and allotted pursuant to the Company's Investor Options, as detailed below.

 

Director/PDMR Shareholding

 

Pursuant to the Exercise, Wensheng Fan, Chief Executive Officer, has exercised
options over 358,572 shares of Common Stock at an exercise price of US$0.20
per share of Common Stock.

 

As a result, Wensheng Fan's beneficial interest in the Company is 1,858,572
shares of Common Stock, representing approximately 1.35% of the total issued
share capital.

 

Admission and Total Voting Rights

 

The Company will apply for 358,572 shares of Common Stock to be admitted to
trading on AIM, with admission expected to take place at 8:00 a.m. on or
around 31 August 2023 ("Admission"). The shares of Common Stock will
rank pari passu in all respects with existing Common Stock. A further
796,587 shares of Common Stock were previously admitted to trading pursuant to
a block listing.

 

Following Admission, there will be 137,404,723 ordinary shares of Common Stock
of US $0.001 each in issue, with one voting right per share of Common Stock.
The total number of voting rights in the Company will therefore be
137,404,723.

 

This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the issued share capital of the
Company under the Company's Certificate of Incorporation. No Common Stock is
held in treasury.

 

Market Abuse Regulation (MAR) Disclosure

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulations
(EU) No. 596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"). Upon the publication of this
announcement via Regulatory Information Service ("RIS"), this inside
information is now considered to be in the public domain.

 

For further information please contact:

 

 Spectral MD Holdings, Ltd.                               IR@Spectralmd.com
 Wensheng Fan, Chief Executive Officer                    via Walbrook PR

 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (NOMAD and Joint Broker for Spectral MD)                        Tel: +44 (0)20 3470 0470
 Stuart Gledhill / Harry Davies-Ball (Corporate Finance)

 Vadim Alexandre / Rob Rees (Sales & Broking)

 The Equity Group Inc. (US Investor Relations)            dsullivan@equityny.com
 Devin Sullivan                                           Tel: 212-836-9608

 Walbrook PR Ltd (UK Media & Investor Relations)          spectralMD@walbrookpr.com
 Paul McManus / Louis Ashe-Jepson / Alice Woodings        Tel: +44 (0)20 7933 8780

 

 

About Spectral MD

 

Spectral MD is a predictive AI company focused on medical diagnostics for
faster and more accurate treatment decisions in wound care for burn, DFU, and
future clinical applications. At Spectral MD, we are a dedicated team of
forward-thinkers striving to revolutionize the management of wound care by
"Seeing the Unknown"® with our DeepView® Wound Diagnostics System. The
Company's DeepView® platform is the only predictive diagnostic device that
offers clinicians an objective and immediate assessment of a wound's healing
potential prior to treatment or other medical intervention. With
algorithm-driven results that substantially exceed the current standard of
care, Spectral MD's diagnostic platform is expected to provide faster and more
accurate treatment insight, significantly improving patient care and clinical
outcomes. For more information, visit the Company at: www.spectralmd.com
(http://www.spectralmd.com) .

 

 

 

 1.    Details of the person discharging managerial responsibilities / person closely
       associated
 a)    Name                                                         Wensheng Fan
 2.    Reason for the Notification
 a)    Position/status                                              CEO
 b)    Initial notification/Amendment                               Initial notification
 3.    Details of the issuer, emission allowance market participant, auction
       platform, auctioneer or auction monitor
 a)    Name                                                         Spectral MD Holdings, Ltd

 b)    LEI                                                          213800VXW1FVGWTCKL44

 4.    Details of the transaction(s): section to be repeated for (i) each type of
       instrument; (ii) each type of transaction; (iii) each date; and (iv) each
       place where transactions have been conducted
 a)    Description of the Financial instrument, type of instrument  Common Stock of US$0.001 each
       Identification code                                          USU8457V1099

 b)    Nature of the transaction                                    Exercise of Options

 c)    Price(s) and volume(s)

Price(s)      Volume(s)
                                                                    1.  US$0.20    358,572

 

 d)    Aggregated information:

Price(s)   Volume(s)
       -   Aggregated volume                                         US$0.20   358,572

       -   Price

 

 e)    Date of the transaction                                      18 August 2023

 f)    Place of the transaction                                     Outside a trading venue

 

 

d)

Aggregated information:

-   Aggregated volume

-   Price

 

 Price(s)   Volume(s)
  US$0.20   358,572

 

 

e)

Date of the transaction

18 August 2023

 

 

f)

Place of the transaction

Outside a trading venue

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEASPSALPDEEA